OncoMatch/Clinical Trials/NCT06252662
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Is NCT06252662 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Dexmedetomidine and Liposomal bupivacaine for breast cancer.
Treatment: Dexmedetomidine · Liposomal bupivacaine — Perform a comparison of effective pain relief duration between liposomal bupivacaine and dexmedetomidine when added to bupivacaine in a block for mastectomy for cancer surgery. The erector spinae plane block is a well-established block that is utilized for post operative pain control for procedures performed on the soft tissue of the chest and chest wall as well as intrathoracic procedures. The goal is comparison of the effective duration of both study groups to determine if there is a significant difference in time and amount of post operative opioids required which admitted to hospital.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Naval Medical Center Portsmouth · Portsmouth, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06252662 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages